GautamBorthakurMD

Hematology • Houston, TX

Hematologic Oncology

Professor, Department of Leukemia, University of Texas Medical School at Houston

Join to view full profile

Dr. Borthakur is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Borthakur's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 2001 - 2004
Brooklyn Hospital CenterResidency, Internal Medicine, 1993 - 1996
Assam Medical CollegeClass of 1985

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 1996 - 2025
OK State Medical License 2020 - 2021
UT State Medical License 1996 - 1998
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Top Doctors:SE Texas Castle Connolly, 2013

Clinical Trials

Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome Start of enrollment: 2009 Jan 01
Completed
Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Start of enrollment: 2007 Apr 04
Recruiting
Phase 2
FTS Study in Patients With Advanced Hematologic Malignancies Start of enrollment: 2006 May 01
Completed
Phase 1
Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage Start of enrollment: 2009 Mar 01
Completed
Phase 2
Study to Assess OPB-31121 in Advanced Leukemias or Myelodysplastic Syndromes Start of enrollment: 2008 Jul 01
Terminated
Phase 1
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy Start of enrollment: 2013 Jun 01
Completed
Phase 1, Phase 2
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients Start of enrollment: 2013 Apr 01
Completed
Phase 2
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL Start of enrollment: 2014 Jun 01
Terminated
Phase 2
A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL Start of enrollment: 2015 Oct 01
Completed
Phase 1, Phase 2
Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Start of enrollment: 2016 May 04
Completed
Phase 1
Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Start of enrollment: 2017 Oct 27
Terminated
Phase 2
A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS Start of enrollment: 2019 Mar 25
Recruiting
Phase 1
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS Start of enrollment: 2019 Aug 02
Completed
Phase 1
A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML Start of enrollment: 2021 Apr 16
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Start of enrollment: 2020 Jan 06
Recruiting
Phase 1
Roles: Contact
A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS) Start of enrollment: 2021 Oct 22
Suspended
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AML Start of enrollment: 2021 Jul 12
Active, not recruiting
Phase 1, Phase 2
Roles: Contact
TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia Start of enrollment: 2020 Mar 27
Completed
Phase 1, Phase 2
Roles: Contact
Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia Start of enrollment: 2022 Apr 05
Recruiting
Phase 1
Roles: Contact
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS Start of enrollment: 2020 Sep 21
Active, not recruiting
Phase 1
Roles: Contact, Principal Investigator
A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia Start of enrollment: 2024 Feb 08
Suspended
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome.
Ian M Bouligny, Guillermo Montalban-Bravo, Koji Sasaki, Naval Daver, Elias Jabbour
Haematologica. 2025-02-20
Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies.
Jayastu Senapati, Sanam Loghavi, Jennifer Marvin-Peek, Guillermo Garcia-Manero, Tapan M Kadia
American Journal of Hematology. 2025-02-08
2 citations
Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic Designation.
Jayastu Senapati, Hagop M Kantarjian, Fadi G Haddad, Nicholas J Short, Gautam Borthakur
American Journal of Hematology. 2025-02-01

Journal Articles

Response Kinetics and Factors Predicting Survival in Core-Binding Factor Leukemia
Hagop Kantarjian, Gautam Borthakur, Tapan Kadia, Nature

Abstracts/Posters

A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Sy...
Gautam M. Borthakur, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)
Gautam M. Borthakur, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm)
Gautam M. Borthakur, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and Therapy
Gautam M. Borthakur, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Determinants of Outcomes of FLT3mut Acute Myeloid Leukemia with First Salvage Therapy
Gautam M. Borthakur, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia
Gautam M. Borthakur, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis
Gautam M. Borthakur, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy
Gautam M. Borthakur, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Comprehensive Analysis of Genotype and Prior Exposures in Therapy-Related Myeloid Neoplasms (t-MNs)
Gautam M. Borthakur, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in O...
Gautam M. Borthakur, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Gautam M. Borthakur, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53
Gautam M. Borthakur, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS)
Gautam M. Borthakur, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Early Intervention with Hypomethylating Agents in Transfusion-Independent Patients with Myelodysplastic Syndrome
Gautam M. Borthakur, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS)
Gautam M. Borthakur, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia
Gautam M. Borthakur, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Impact of PHF6 Mutations in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
Gautam M. Borthakur, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute...
Gautam M. Borthakur, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
Gautam M. Borthakur, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome
Gautam M. Borthakur, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
Gautam M. Borthakur, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)
Gautam M. Borthakur, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remis...
Gautam M. Borthakur, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes
Gautam M. Borthakur, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcomes of Patients with Suboptimal /Warning Response to Tyrosine Kinase Inhibitors: A Comparison of the 2009 and 2013 Guidelines of the European Leukemianet
Gautam M. Borthakur, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Patients with Relapsed or Refractory AML or MDS
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Mechanisms Underlying Superior Efficacy of Co-Targeting BET Proteins and Anti-Apoptotic BCL2 or MCL1 Protein Against AML Blast Progenitor Cells
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Interim Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with Untreated Acute Myeloid Leukemia (AML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromoso...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Evolutionary Action Score of Missense TP53 Mutations Can Predict Outcome in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Authored Content

A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (Pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)October 2017
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) Treatment for First-Line Therapy of Patients with CLL with Mutated IGHV and Without Deletion 17pOctober 2017
The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II TrialOctober 2017